Search Results for "Meda Consumer Pharmaceutical"
Original Source: MEDA AB
Meda is one of Europe's leading specialty pharma companies. Meda covers all of Europe via its subsidiaries in more than 20 European countries; it has 900 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuticals. Specialisation occurs within marketing and market-adapted product development. A key part of its product flow is also created through partnerships, in-licensing, and product acquisitions. Meda's pan-European marketing organisa...
Matching Channels
Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales. With bases in 47 c...
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals,...
China has the fastest growing economy in the world, and the fastest growing uptake of technology in the world. Not surprisingly, its biotechnology industry is booming. Its potential not only as a pr...
The Top 100 Pharmaceutical Companies
The Top 100 Pharmaceutical Companies, determined by total sales in 2011 - see below for 2010 and 2009: They are listed in descending order with the sales in 2011 in $ million; Pfizer ...
GMO Crops - news, views, reports
Transgenic plants have been engineered to possess several desirable traits, such as resistance to pests, herbicides, or harsh environmental conditions, improved product shelf life, and increased nut...
Matching News
Meda's Zyclara approved in the EU
Sweden-based Meda (OMX: MEDA A) yesterday announced that the European Commission has granted marketing authorization for Zyclara (imiquimod 3.75% cream), a patented product for the treatment of actini...
MEDA AB (publ) NOTICE OF ANNUAL GENERAL MEETING 2013
Regulatory News: Notice is hereby given that the Annual General Meeting (AGM) of Meda AB, corporate ID 556427-2812, will be held at 5.00 PM on Tuesday, May 7, 2013, at Meda's headquarters at Piper...
Jazz Pharma sells women's health business to Meda for $95 million
US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced a definitive agreement to sell its women's health business, which includes six products, to Sweden-based Meda (OMX: MEDA) for $95 milli...
News briefs: Meda's Edluar; DebiopharmAscepion; MallinckrodtHorizon
Swedish drugmaker Meda AB (OMX: MEDA A) says that is Edluar, an oral sublingual formulation of zolpidem, has received registration approval in Europe via the decentralized procedure with Sweden acting...
Jazz Pharma completes women's health unit sale
Irish drugmaker Jazz Pharmaceuticals PLC said Monday that it completed the sale of its women's health business to Swedish pharmaceutical company Meda AB.Jazz agreed to sell the business to Meda in Se...
Regulatory News: At the annual general meeting (AGM) on May 7, 2013, of Meda AB (publ)(STO:MEDAA), corporate ID 556427-2812, Box 906, SE-170 09 Solna, Sweden, declared a dividend of 2,25 SEK per s...
Meda's Dymista approved for allergic rhinitis
Meda AB (SSE:MEDAA) said its Dymista azelastine/fluticasone was approved under the EU's decentralized procedure to treat seasonal and perennial allergic rhinitis. Germany acted as the reference member...
Meda to take over Jazz women's health business
Jazz Pharmaceuticals has entered into a definitive agreement to sell its women's health business to Meda, a specialty pharmaceutical company, for $95m in cash.
Matching PubMed Articles
Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.
"Ecstasy" (3,4-methylenedioxymethamphetamine or MDMA) is a widely abused recreational drug, reported to produce neurotoxic effects, both in laboratory animals and in humans. MDMA metabolites can be ma...
This study examined the relationship between insight and mental health consumers and providers agreement regarding consumers rated quality of life (QoL). Seventy mental health consumers and their 23 c...
Health System Implications of Direct-to-Consumer Personal Genome Testing.
Direct-to-consumer personal genome testing is now widely available to consumers. Proponents argue that knowledge is power but critics worry about consumer safety and potential harms resulting from mis...
Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes.
Background and purpose: 3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a worldwide major drug of abuse known to elicit neurotoxic effects. The mechanisms underlying the neurotoxic effects of...
The level of consumer information about health insurance in Nanjing, China.
The Chinese government is considering a (regulated) competitive healthcare system. Sufficient consumer information is a crucial pre-condition to benefit from such a change. We conducted a survey on th...
